- Title
- A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes
- Creators
- Hanny Al-Samkari - Harvard Medical SchoolPierre Fenaux - Assistance Publique – Hôpitaux de ParisMikkael A. Sekeres - Sylvester Comprehensive Cancer CenterEytan Stein - Memorial Sloan Kettering Cancer CenterDavid A. Sallman - Moffitt Cancer CenterAndrew M. Brunner - Harvard Medical SchoolXiaoshu D. Gurov - Agios PharmaceuticalsOphelia Yin - Agios PharmaceuticalsMeghan Frisbie - Agios PharmaceuticalsJames Xiao - Agios PharmaceuticalsJoy Bhatia - Agios PharmaceuticalsVanessa Beynon - Agios PharmaceuticalsMegan Wind-Rotolo - Agios PharmaceuticalsMelissa Dibacco - Agios PharmaceuticalsUwe Platzbecker - University Hospital Leipzig
- Publication Details
- Blood, Vol.140(Supplement 1), pp.4076-4078
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031760089402976
Journal article
A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes
Blood, Vol.140(Supplement 1), pp.4076-4078
2022-11-15
Metrics
2 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Citation topics
- 3 Agriculture, Environment & Ecology
- 3.180 Microbial Biotechnology
- 3.180.1338 Phosphofructokinase
- Web Of Science research areas
- Hematology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites